Gland Pharma

Gland Pharma Limited API manufacturing facilities are located in Vizag and Hyderabad equipped with in house Pharmaceutical manufacturing facilities.

Gland Pharma Limited engages in Formulation Research and Development, Analytical Research and Development, API Process Development & Stability Studies, also expertise in synthesis of complex drug molecules.

Gland Pharma Limited pharamaceutical formulation manufacturing facilities are located in Hyderabad and Vizag which are equipped for injectables production.

Gland Pharma Limited is present in a vast range of therapeutic API categories that include Anti-Infectives, Anti-Coagulants and their Antidotes, Anti-Malarial, Cardiology and etc.

Follow our news room everyday to stay updated about the Gland Pharma latest news, Achievements & api products.

Stock exchange announcements from Gland Pharma company show information on analyst’s meetings, share price, ipo, investor’s meetings, board meetings, and monitoring agency annual reports.

Gland Pharma Limited licensing involves global out-licensing in both regulated and semi-regulated market with both early-stage licensing and late-stage licensing of Products.

Gland Pharma's Corporate Social Responsibility (CSR) focuses mainly on health & wellness, environmental sustainability, education of the unprivileged section.

Gland Pharma Limited is a CDMO pharma company and injectable manufacturer and adopts B2C model solely in india through a field force of employees and a distribution network.

Gland Pharma Limited is a leading CDMO pharma company supplying Generic & complex injectables to India, USA , Europe, Canada, Australia, and the Rest of the world.

Contact Gland Pharma Limited for investment & investment related queries.

Gland Pharma’s Business Development Team supports the development, manufacturing, and supply of finished dose products.

Gland Pharma reports a **58% year-over-year net profit increase** to ₹291 crore in Q2 FY27, driven by strong business execution. The company’s **contract development and manufacturing organization (CDMO) revenue rises by 31%**, contributing to financial growth.

Nov 2026CNBCTV18News article

Gland Pharma secures U.S. approval for its methylprednisolone acetate injectable suspension in single-dose and multiple-dose vials. The product adheres to USP (United States Pharmacopeia) standards, expanding the company’s pharmaceutical portfolio. This approval supports Gland Pharma’s growth in the injectable steroid formulations market.

Nov 2026TradingViewNews article

Gland Pharma Ltd discloses a significant investment under Regulation 30 of the Lodr. The company also reports the resignation of one director and the appointment of a new director. These updates reflect leadership changes and financial adjustments within the pharmaceutical firm.

Oct 2026Arthneeti AINews article

Gland Pharma secures a strategic contract with a global pharmaceutical company to manufacture and supply sterile injectable products. The deal covers 55 product SKUs across three facilities and targets $90–100 million in annual revenue upon full commercialization, with revenue expected to start in 2029.

Aug 2026The Economic TimesNews article